Athena Heart [310] 〈Mobile Certified〉

: To determine if dronedarone could lower the risk of hospitalization due to cardiovascular events or death from any cause in patients with atrial fibrillation (AF) or atrial flutter (AFL).

It is intended to reduce the risk of hospitalization for AF. 3. Safety and Contraindications ATHENA HEART [310]

: Conduct regular ECGs to monitor for potential proarrhythmic effects or excessive QT prolongation. : To determine if dronedarone could lower the

: Dronedarone significantly reduced the primary composite endpoint of first cardiovascular hospitalization or death by 24% compared to a placebo. ATHENA HEART [310]

Clinicians should monitor several factors to prevent adverse outcomes: